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The Chinese Health Improvement Profile (CHIP) for people with severe mental 
illness: A Cluster Randomised Controlled Trial 
 
Abstract  
 
This study aimed to establish the feasibility of conducting a full-scale trial and estimate the preliminary effect 
of a Chinese Health Improvement Profile (CHIP) intervention on self-reported physical well-being of people 
with Severe Mental Illness (SMI).  The study used a parallel group, open label, cluster-randomised controlled 
trial design. 12 Community Psychiatric Nurses (CPNs) and their corresponding 137 patients with SMI were 
randomised into the CHIP or treatment-as-usual (TAU) groups. After training the CPNs completed the CHIP 
at baseline and 12 months and the findings were used to devise an individualised care plan to promote 
health-behaviour change. Patients were assessed at baseline, 6 and 12 months after starting the 
intervention. There was an observed positive trend of improvement on the physical component subscale 
(PCS-12) of SF12v2 in the CHIP group compared to the TAU group after 12 months, but the difference did 
not reach statistical significance (p=0.138). The mental component subscale (MCS-12) showed a similar 
positive trend (p=0.077). CHIP participants were more satisfied with their physical healthcare than TAU 
patients (p=0.009) and the CPNs were positive about the usefulness/acceptability of the intervention. There 
were significant within-group improvements in the total numbers of physical health risks as indicated by the 
CHIP items (p=.005). The findings suggest that it is feasible to conduct a full-scale RCT of the CHIP in future. 
The CHIP is an intervention that can be used within routine CPN practice and could result in small-modest 
improvements in the physical well-being of people with SMI.  
 
Trial registration:  
Clinicaltrials.gov reference number NCT02453217 
 
Keywords:   
 
Physical Health; Severe Mental Illness; SF12v2; Chinese Health Improvement Profile.    
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Introduction  
 
People with severe and enduring mental illness (SMI) have an elevated risk of developing physical health 
problems which contribute towards high mortality rates (DeHert, et al., 2011; Brown, Inskip and Barraclough, 
2000; Chesney et al. 2014). It has been estimated that people diagnosed with a SMI die between 10 and 30 
years earlier than the general population (DeHert et al. 2011; Happell et al., 2011; Walker et al. 2015).  The 
most common physical health problems that have been associated with SMI are cardiovascular disease, 
metabolic disorders, obesity, some cancers, and respiratory conditions (Robson and Gray, 2007; 
Vancampfort et al. 2015; Gardner-Sood et al. 2015). The majority of premature deaths in this patient group 
are attributed to cardiovascular diseases (CVD) (McEvoy et al., 2005; Lawrence et al. 2013). 
 
In response researchers have conducted trials focused on reducing the cardiometabolic health risks of 
people with SMI. Many studies have aimed to change health behaviours (e.g. physical activity or diet) in 
order to reduce CVD risk factors such as obesity (Buka, 2008; Ellis et al., 2007; Saxena et al., 2005; 
Rosenbaum et al. 2014; Firth et al., 2015). Two systematic reviews of intervention studies that aim to 
improve physical health in SMI (Happell, Davies and Scott, 2012; Soundy et al. 2014) concluded that 
interventions may result in significant benefits for health behaviours and cardiometabolic health; including 
improvements in diet, alcohol use, exercise, smoking and weight management but the effect sizes were 
small.  
 
Regular physical health monitoring for people with SMI is recommended in the National Clinical Guidelines 
of many countries (American Psychiatric Association, 2004; Department of Health, 2016; National Institute 
for Health and Care Excellence, 2014). There is some preliminary evidence that lifestyle intervention 
programmes which comprehensively assess lifestyle behaviours and physical health can help to inform 
patient-centred care planning and subsequently result in the improved health behaviours of patients with 
SMI (Ohlsen et al., 2005; Eldridge et al., 2011; White et al, 2009; Bressington et al., 2014). Similarly, Van 
Meijel et al (2014) reported that a “traffic light method” of conducting a health check (where areas of risk 
are highlighted as red lights) resulted in statistically significant reductions in the mean waist circumference 
measurement and weight of people with SMI.  The Health Improvement Profile (HIP; White, Gray and Jones, 
2009) is intended for use by psychiatric nurses to assess areas of potential health risks e.g. levels of physical 
activity, lipid and blood glucose levels, quality of diet, oral health. The authors then recommend developing 
with the patient an individualised physical health care plan, utilising motivational interviewing approaches 
to promote behaviour change during regular routine clinical meetings. This approach is also supported by 
the findings of some studies that have used educational approaches and motivational interviewing as a part 
of an intervention package with SMI patients and which have resulted in significant improvements in levels 
of understanding about nutrition/exercise (Wirshing et al., 2006), reductions in body weight (mean weight 
loss of 2.7 kg) (Veerland et al., 2003) and clinically significant reduction in cardiovascular risk (Bartels et al., 
2013).   
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This study builds on our previous work in this area. We reported a prospective case series using the HIP in 
148 patients in Hong Kong (Bressington et al., 2014). Over twelve months we observed significant increases 
in participants’ self-reported amounts of exercise (19 participants increased their levels of exercise to 
recommended limits). We also completed a quasi-experimental before-and-after study of the HIP in 105 SMI 
patients in Thailand (Meepring et al., 2016). We observed improvements in Body Mass Index (-0.78 kg/m2, 
p<.001), with 23 patients (22%) shifting to a healthier Body Mass Index classification at one-year follow-up. 
There were also significant improvements in the total number of “red-flagged” HIP items (p<.001). The HIP 
intervention and tool was modified for use in Hong Kong based on our previous research findings 
(Bressington et al., 2014; 2016) to develop the Chinese Health Improvement Profile (CHIP), which is tested 
in this pilot cluster RCT. The modifications included translation into Chinese language, revisions to 
supporting/educational materials, terminology changes and the introduction of a “traffic-light” warning 
system to highlight the health relevance of findings for all individual CHIP items.  
 
Study aims 
 
The main aims of this study were to estimate the preliminary effect size of the CHIP on the perceived physical 
well-being of people with SMI and establish the feasibility of conducting a full-scale trial. 
 
Primary objective: 
 
 To determine the preliminary effect size of the CHIP on the perceived physical well-being of patients 
with severe mental illness at 6 and 12-months after intervention commencement compared to 
treatment as usual (TAU).  
 
Secondary objectives: 
 
 To determine if, compared to TAU, the CHIP enhances perceived mental well-being at 6 and 12 
months after the intervention started. 
 To establish changes in health behaviours and physical health risks within the intervention group 
between baseline and at 12 months. 
 To establish differences in the objective physical health state of patients between the two groups at 
12 months as indicated by data routinely recorded in medical/outpatient/nursing notes during the 
study duration.    
 To determine if, compared to TAU, the CHIP participants were more satisfied with their physical 
health care at 12 months.   
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 To ascertain CPNs perspectives about the perceived acceptability and usefulness of the CHIP 
intervention at 12 months.   
 
Design:    
This pilot study used a parallel group, open label, clustered randomised controlled trial design. Community 
Psychiatric Nurses (CPNs) and their corresponding randomly selected eligible patients were randomised into 
either the CHIP or TAU group after all baseline measures were completed. The CPNs in the intervention group 
received one-day CHIP training after random allocation and were instructed to complete the CHIP at baseline 
and again after 12 months. Patients’ outcomes were assessed at baseline, 6 and 12 months. The trial protocol 
was registered with Clinicaltrials.gov (NCT02453217) before the study commenced. We have carefully 
followed CONSORT when reporting the findings from this pilot trial. 
     
Study setting: 
The study was carried out in a Community Psychiatric Nursing Service in Hong Kong between July 2015 and 
October 2016. The multi-disciplinary psychiatric service is attached to a large psychiatric hospital in the New 
Territories and provides community mental health services for the local population of approximately 1.1 
million people.   
 
Ethical considerations 
Ethical approvals for the study were obtained from the University’s Research Ethics Committee (reference: 
HSEARS20141202001) and the Hong Kong Hospital Authority Cluster Clinical Research Ethics Committee 
(reference: NTWC/CREC/15007). Patient participants were given written information and allowed at least a 
day to consider their decision. All participants provided their written informed consent to take part in the 
study and patients were additionally asked for their permission for their medical notes to be reviewed. All 
participants were informed that they were entitled to withdraw from the study at any time without having 
to give a reason, and without negative consequences.    
 
Recruitment: 
The lead clinician of the participating community mental health team was asked to nominate CPNs who met 
the study inclusion criteria. After discussions with the clinical team leader we decided that we would aim for 
12 CPNs to take part in the study. This decision was made because approximately 140 participants would be 
required for detecting a medium-large effect on perceived physical well-being and we aimed to ensure that 
each CPN participant had a manageable additional workload (i.e. each using the HIP intervention with less 
than 15 patients). A research assistant visited the CPNs who expressed an interest in participating to explain 
the study, provide any required additional written information and obtain informed consent.  
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The consenting CPNs case lists were screened by the clinical team leader to identify potentially eligible 
patients.  All eligible patients from each CPNs list were given a unique number based on the alphabetical 
order of their surname. An online programme (researchrandomiser.org) was used to generate a separate set 
of 15 random numbers corresponding to individual patients on each CPN’s case list. These numbers were 
used to determine which patients were approached for informed written consent to take part in the study 
and each CPN met with these randomly selected patients in numerical order until a minimum of 12 had 
agreed to take part. Baseline data collection was then carried out with the consenting patients. 
 
Random treatment allocation 
After patient recruitment and baseline data collection were completed the CPNs (and their corresponding 
patients) were randomly allocated to either the CHIP or TAU group.  The random treatment allocation was 
conducted by an external researcher with an online system (sealedenvelope.com) using random permuted 
blocks to ensure balanced group numbers.   [See figure 1 for CONSORT diagram summary of trial design] 
 
Inclusion criteria (CPNs) 
Male or female, registered psychiatric nurses with a minimum of 5 years’ post-qualification experience 
working with community-dwelling SMI patients in Hong Kong.  
 
Inclusion criteria (patients) 
Female or male adult patients (18-65), able to understand Chinese or English, with a ICD-10 diagnosis of SMI 
(classified as schizophrenia, schizoaffective disorder, other psychotic disorder, bipolar affective disorder 
[type 1 or 2] or major depressive disorder).  
 
Sample size: 
This is a pilot study and the main objective is to provide information about required sample sizes for the 
main trial; therefore, we were unable to take reference from any previous CHIP study and our sample size 
calculation was based on a standard deviation of around 12 points for the SF36v2/SF12v2 PCS observed in 
SMI patients and an estimated mean difference of 6 points on this scale between intervention and TAU 
groups (suggestive of a medium-to-large effect size) (White et al., 2011; Lam et al., 2013). As the 12 CPNs 
involved in the study were the clustered units of randomisation we also needed to adjust the sample size 
calculation accordingly. Assuming an intraclass correlation of 0.15 (White et al., 2011) and a significance level 
of 0.05, we calculated that for a medium (0.5) effect size the number of patients required would be 21 per 
nurse and for a large (0.8) effect size we would need 3 patients per nurse.  Given that our previous case 
series study (Bressington et al., 2014) demonstrated patient attrition was approximately 29%, we inflated 
our sample size accordingly. Therefore, as this pilot study aimed to detect a medium-large effect size, the 12 
CPNs were asked to recruit and (where appropriate) deliver the intervention to 12 patients each that were 
randomly selected from their caseloads (effectively 72 in each group). 
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Intervention: 
CPNs allocated to the intervention group used the CHIP to assess patients’ physical health risk and identify 
problem health and lifestyle behaviours. The CHIP tool consists of 27 areas of physical health assessment for 
men and 28 areas for women (including BMI, waist circumference, blood pressure, pulse, cholesterol levels, 
dietary habits, exercise levels, fluid intake, alcohol use, substance misuse, self-checking behaviours, smoking 
status, regularity of health check-ups, bowel habits, sleep, urination concerns, caffeine intake, sexual 
functioning and safe-sex practices), it also provides information about healthy parameters and suggestions 
for evidenced-based interventions to address areas of identified health risks.  In line with the procedures 
described by White, Gray and Jones (2009) and Shuel et al (2010), findings from the assessment were used 
to inform an individualised care plan with community based patients with SMI. CPNs were encouraged to 
use this plan to liaise with medical colleagues to refer patients for further investigation or treatment as 
required. The CHIP used a traffic light system to indicate area of physical health risk that require attention 
(green= no action required; yellow= caution; red=action required). The yellow (caution) flag was used for the 
majority of items except those with well-defined cut-off parameters (BMI, waist circumference, pulse, blood 
pressure, liver function, prostate/testicles check, cervical smear test, feet check, breast check, menstrual 
cycle and smoking status). The CPNs then used brief motivational interviewing techniques and principles to 
have conversations about and support health behaviour change (as outlined by Hardy, White and Gray, 2015; 
White et al., 2011; Meerpring et al., 2016) during monthly follow-up meetings. Each completion of the CHIP 
tool takes around 25 minutes and CPNs were expected to discuss/review the care plans for a minimum of 15 
minutes each month. The overall emphasis of the intervention was to raise patients’ awareness of their own 
physical health and encourage self-management/behaviour change. 
 
CHIP training: 
The CPNs in the intervention group attended a one-day training workshop (facilitated by DB, KL and JM).  The 
learning outcomes from the workshop were: 1. using the CHIP, 2. behaviour change conversations using brief 
motivational interviewing techniques, and 3. care planning and follow-up. Participants who attended 
reported that they felt confident that they had an adequate level of skills and a good understanding of the 
CHIP intervention prior to using the intervention with their patients. They were all provided with clinical 
supervision in monthly meetings with their team supervisors as well as 6-monthly multidisciplinary case 
meetings chaired by the consultant psychiatrist; other than these usual regular meetings no extra support 
was required.    
 
Treatment as usual: 
 
Patients in both the intervention and control groups received routine community mental health services and 
attended psychiatric outpatient appointments as required. Both patient groups also received annual basic 
physical health screening (as specified by the policy of the clinical setting for people taking antipsychotics) 
to measure waist circumference, BMI, blood glucose, cholesterol levels and blood pressure.        
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Outcome measures: 
 
Patients’ outcomes (SF12v2) were measured at baseline and 6 and 12 months after starting the intervention.  
Relevant demographic/clinical patient data were recorded at baseline and at 12 months.  Data relating to 
the participants’ physical health state that had been routinely recorded over the one-year duration of the 
study were extracted from their integrated medical records. These data included indicators of 
cardiometabolic health recorded by nursing staff (i.e. body temperature, waist circumference, weight, BMI, 
heart rate, blood pressure,) and relevant blood test results (i.e. cholesterol, liver function, prolactin levels, 
fasting blood glucose levels). 
 
Intervention and TAU groups: 
Patients physical well-being was measured using the physical component subscale (PCS) of the SF12v2. 
Perceived mental health was determined using the mental component subscale (MCS) of SF12v2. The SF12v2 
(Ware et al. 2000) is modified from the original SF36 and includes 12 questions (Ware et al., 1994). The Hong 
Kong version of the SF12v2 is reporting as having acceptable test–retest reliability (intraclass correlation 
0.82) and also has acceptable internal consistency (Cronbach’s alpha 0.67). Sensitivity and construct validity 
were also confirmed in a Chinese population (Lam et al., 2013).   
 
Data relating to patients’ physical state that are routinely recorded in medical/outpatient/nursing notes 
during the study were also compared between the two groups.   
 
Intervention group only: 
Data recorded from the individual items of the CHIP (red flagged physical health risks and health behaviours) 
were compared between baseline and at 12 months after the start of the intervention.  We also identified 
the numbers of individual participants that improved or deteriorated in terms of their CHIP item classification 
over the duration of the study.  
 
Ascertaining the acceptability of CHIP intervention programme: 
In order to measure patients’ views about their satisfaction with their physical health care (treatment as 
usual and CHIP intervention programme group) we asked all patients to complete the Chinese language 
version of the Client Satisfaction Questionnaire (CSQ8) (Attkisson and Zwick, 1982; Attkisson, 2012) 12 
months after the intervention. The CSQ8 is a well-established standardised self-report measure of 
client/patient satisfaction with a service or intervention. It consists of 8 Likert scale questions and has been 
used in many patient groups and service settings; including physical and mental health conditions. It is 
reported to have excellent reliability and internal consistency (Attkisson and Zwick, 1982).  In order to 
ascertain CPNs perspectives about the perceived acceptability and usefulness of the CHIP intervention at 12 
months’ follow-up we asked all participants in the intervention group to complete a simple questionnaire 
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containing two 8-point Likert scale questions of “usefulness” and “acceptability” of the CHIP on scale from 1 
(not at all) to 9 (very useful) and an optional box for additional feedback.  
 
Intervention fidelity: 
CPNs fidelity to the CHIP intervention was established through a clinical notes audit of a randomly selected 
group of participants. All participants from the intervention group were assigned a new number and 20% 
(N=14) of the CHIP patients were randomly chosen using a list of computer-generated numbers (using 
researchrandomiser.org).  At 12 months, 2 researchers examined the medical and nursing notes of these 
randomly selected patients. The notes were checked to establish how many recommendations/interventions 
identified using the CHIP were also mentioned in the participants’ care plans. 
 
Data analysis  
 
Intervention and TAU groups 
 
Baseline characteristics were summarized and compared between the study groups (table 1). The primary 
analysis included comparing the primary outcome of PCS-12 at 12 months between the study groups using 
the one-way analysis of variance (ANOVA) with adjustment for the possible clustering effect among the 
nurses (table 2). The Intra-class correlation coefficient was computed. The secondary analyses included 
performing similar analysis for the PCS-12 score at 6 months and for the MCS-12 scores at 6 and 12 months 
and several secondary variables such as BMI, waist circumference, blood pressure, pulse and total 
cholesterol. Moreover, the analyses were adjusted for the baseline values in PCS-12 and MCS-12 using one-
way analysis of covariance (ANCOVA) that also adjusts for the clustering effect. Independent t-tests were 
utilised to measure differences between the two groups on CSQ8 scores at 12 months’ follow-up.  The 
intention to treat (ITT) was used throughout all analyses with missing data from randomised patients 
imputed using the overall mean values at each time point.   
 
Intervention group only: 
McNemar tests, Wilcoxon signed rank test, paired T-tests or Freidman’s’ two-way ANOVA (dependent on the 
variable type and distribution of data) were used to analyse differences between baseline and follow-up data 
on frequency of red/green/yellow flagged health behaviours and physical health parameters recorded on 
the CHIP tool within the intervention group. These analyses provided an indication of within-group changes 
in self-reported health behaviours and physical indicators of physical health risk that are recorded as part of 
the CHIP intervention. 
 
Results 
Figure 1 shows the flow of CPNs and patients through the trial. A total of 165 eligible outpatients (15 per 
CPN) were randomly selected and approached to take part, of these, 141 (85%) consented to take part and 
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were assessed at baseline. The remaining 23 (15%) expressed no interest in completing the CHIP, and one 
received a diagnostic change during the recruitment period necessitating exclusion from the study. Of the 
141 patients who provided initial consent, 4 were withdrawn from the study prior to randomisation (two 
were moved under the care of a different CPN and two were discharged from CPS). Recruitment of 
participants to the study was completed in September 2015.     
 
12 CPNs were randomized into either the Treatment as Usual (TAU) group or the Chinese Health 
Improvement Profile (CHIP) intervention group by September, 2015, resulting in 69 patients randomized into 
the CHIP group and 68 patients into the TAU group. Both groups completed their 6-month follow-up 
outcome measures by March 2016, with one CHIP patient lost to follow-up (discharged from the service). 
The 12 months’ follow-up measures were completed between June and September 2016, with 10 patients 
from CHIP and 4 patients from TAU were further lost to follow-up. Reasons for attrition were:  3 patients 
required case managerial changes due to operational reasons, one patient moved out of area, 2 cases due 
to hospital readmission, 5 participants refused to complete outcome measures and 4 patients were 
discharged from the service (completed treatment). In accordance with the a-priori intention-to-treat 
analysis strategy 69 patients in the CHIP group and 68 TAU patients were included in the final analysis.  No 
significant physical health related adverse effects were reported as a result of the intervention throughout 
the study, however two patients in the CHIP group were admitted to hospital for relapse of mental illness.       
 
Baseline demographic and clinical characteristics 
 
The baseline demographic and clinical characteristics of participants are provided in table 1.  Overall, the 
patients in both groups were predominantly middle-aged with a mean of 47.8 years (SD= 9.2) in the CHIP 
group and mean of 46.8 years (SD=10.4) in the TAU group. On average the patients had a duration of illness 
of around 14 years. Over half (55%) were diagnosed with schizophrenia and two thirds (64%) were being 
treated with atypical antipsychotic medications. Most of the baseline characteristics were not different 
between the two study groups except for Dyslipidaemia (p=0.06), Pulse (p=0.001) and Systolic Blood 
Pressure (p=0.03). 
 
Primary and secondary outcomes 
Table 2 shows the analysis results for the primary and table 3 shows the secondary outcome measures.  
 
There was a positive trend of changes in the mean PCS-12 scores of the CHIP group throughout the study, 
with a 2.6 mean increase from baseline to 6 months, and a further increase of 1.1 from 6 to 12 months. As 
opposed to the TAU group in which the PCS-12 scores initially increased from baseline to 6 months (mean 
difference of 2.2), before deteriorating by 0.6 to a mean score of 47.5 at 12 months. However, at 12 months 
there was no statistically significant difference found in the mean PCS-12 scores between the two study 
groups (50.7 in the CHIP vs. 47.5 in the TAU group, p=0.149). The ICC was 0.158 for the cluster effect. The 
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results did not change greatly when the analysis was adjusted for baseline values (mean difference of 2.7, 
p=0.138). The preliminary effect size of the differences between CHIP and TAU groups in mean PCS-12 scores 
at one-year is calculated as Cohen’s d=0.42.  
 
Positive trends were also observed for the MCS-12 scores, with steady improvements for the CHIP group 
throughout the study (increase in mean MCS-12 score of 5) compared to the TAU group (overall increase of 
0.8). However, similarly to the primary outcomes, the differences for the MCS12 score (adjusted for baseline 
scores) between the two groups at 12 months did not reach statistical significance (p=0.077).  Table 3 shows 
the data analysis for the secondary outcomes. Except for pulse where participants in the CHIP group had 
significantly lower mean than those in the TAU group (p=0.006), none of the other secondary variables 
considered were significantly different between the study groups at 12 months.  
 
Within-group CHIP item changes  
Table 4 provides details of the CHIP items at baseline and 12-months. The results show there are significant 
(within CHIP group) improvements in the frequencies of red/yellow/green flagged individual items for 
Prostate/testicles checks (p=0.025), Feet checks (p<0.001), Breast checks (p=0.002), Diet (fruit and 
vegetables; p=0.008), Diet (rice; p=0.041), Fluid intake (p=0.001), Total Red flags (Z=-2.81, p=.005) and Total 
Green flags (Z=-3.13, p=.002). The percentage of women with concerns about their menstrual cycle was the 
only item observed to have significantly deteriorated (p=0.021).  The numbers of individual participants that 
improved or deteriorated in terms of their classification are also detailed in table 4.   
 
Patient satisfaction 
Analysis of the CSQ8 scores at 12 months’ revealed that participants in the CHIP group (mean 26.68) were 
significantly more satisfied with their physical health care provision than those patients in the TAU group 
(mean 25.41) with a mean difference of 1.27 (p=0.009, T -2.67, df135, 95% CI -2.21 to -0.33).  
 
Nurse perceived usefulness and acceptability 
The six CHIP CPNs scored the mean perceived usefulness of the intervention as 7.5/9 (range 7-9, median=7) 
and acceptability as 7.1/9 (range 6-9, median=7). The majority (5) commented that the use of the CHIP 
intervention helped to effectively raise patient’s awareness (or insight) of their physical health status and 
was a useful approach to help the CPNs motivate patients to make positive lifestyle behaviour changes. 
Identified areas for improvement were mentioned by two nurses; the first suggested to abandon using the 
carbon backed paper used to copy writing onto the patient copy of the CHIP tool (as this was felt to be too 
messy/unclear) and the second felt that it would be more acceptable if the amount of writing required of 
the CPN could be reduced.  
 
Intervention fidelity  
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The review of randomly selected patients notes showed that whilst every CPN highlighted more than one 
recommendation and written advice for further investigation on the CHIP form, only 50% (N=7) of the 14 
patient care plans examined included such advice. However, noting that the design of the CHIP form 
expected CPNs to provide a copy of the completed tool directly to the patient, the lack of inclusion of all 
information/advice in the care plans may have been expected, particularly in view of the necessarily brief 
nature of their case notes.  
 
Discussion 
 
There was an observed positive trend of improvement on PCS-12 and MCS-12 scores in the CHIP group 
compared to the TAU group after 12 months. However, these improvements did not reach statistical 
significance, primarily because the sample size was inadequate for the present pilot study to detect 
significant differences as it was calculated assuming a medium to large effect size.  
 
The significant within-group improvements in frequencies of red/yellow/green CHIP flagged items suggest 
that the intervention has raised the participants’ awareness of the need to focus on their physical health and 
associated health-behaviours. However, on this occasion these modest positive changes have not resulted 
in statistically significant improvements in the primary or secondary study outcomes.   It is possible that these 
small improvements could continue after the 12-month period and it would be beneficial for future studies 
to conduct a longer term follow-up to measure effects post-one year. The lack of improvements in the main 
study outcome measure may relate to the relatively high baseline scores of participants (measured using the 
SF12v2), hence creating a ceiling limit for potential improvements. For example, published norm-based 
scores (Lam et al., 2013) suggest that within a Chinese population of people with diagnosis of a psychological 
illness the mean score of the SF12v2 PCS is 44.13, whereas the baseline scores in the current study for the 
CHIP and TAU groups were 47.0 and 45.9 respectively. Despite this ceiling limit, the one-year PCS-12 scores 
in the CHIP group (50.7) increased to levels in excess of norm-based scores for the Hong Kong population 
aged 41-64 years (49.23) (Lam et al., 2013).   In addition, as the CHIP was only used at baseline and at 12-
month follow-up (in accordance with the original HIP procedures (White et al., 2009; Shuel et al., 2010; White 
et al., 2011), it is possible that this may not be an adequate “dose” of the intervention, therefore we would 
suggest increasing the frequency of completion to 3 or 6 monthly over a duration of one year. Another 
potential reason for the lack of significant differences between the two groups may arguably be because the 
increased attention of mental health nurses towards the physical health of service users and sharing of 
information has created a generally more positive environment for monitoring and managing physical health 
(i.e. that the service has improved for all participants). However, the higher satisfaction scores seen in the 
CHIP group do seem to indicate that even if the service had improved generally, the CHIP participants were 
still more satisfied than those in the TAU group.    
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The participants in this study reported relatively low levels of substance use. Compared to HIP participants 
in Scotland (Shuel et al., 2010) service users in the current study had lower frequencies of red-flagged items 
for caffeine intake (0% vs 6.5%), alcohol (3% vs 19%) and drug use (1% vs 7%). However, there was higher 
percentage of smokers in Hong Kong (35%) than in Scotland (26%). Whilst HIP findings from an inpatient HIP 
study in the UK (White, 2015) show that rates of red-flagged items were higher than Hong Kong for alcohol 
use (45%), caffeine intake (33%, smoking (54%) and drug use (25%). It is possible that participants in the 
current study may have underreported their use of substances, but the frequency of red-flagged items for 
substance use in the current study are broadly similar to our earlier case series study (Bressington et al., 
2014) which was carried out in the same clinical setting (alcohol 6%, smoking 27%, caffeine 5%). There are 
very few other studies which have reported the health behaviours of people with SMI in South East Asia, 
however; one HIP study conducted in Thailand (Thongsai et al., 2016) reports lower percentages of red-flags 
than Hong Kong in most substance use areas (alcohol 2%, smoking 12%, illegal drugs 7%). This body of 
evidence seems to show that mental health nurses in some South-East Asian countries may face less 
substance use related health promotion challenges than their counterparts in Western countries. Despite 
this, one of the main challenges for mental health nurses in Hong Kong relates to the high numbers of 
patients who are obese (55%).     
 
Much effort has been put into testing interventions to reduce the bodyweight of SMI patients with pre-
existing cardiometabolic health risks, unfortunately the vast majority of evidence suggests that completely 
reversing these risks is extremely difficult (Attux et al., 2011; Mitchell and DeHert, 2015). The mean age of 
participants in the current study was 47 years and average duration of illness was 14 years, it is certainly 
possible that marked changes are less likely for older patients and those with long history of SMI (Mitchell 
and DeHert, 2015; Bonfioli et al., 2012), and therefore this may account for the lack of improvement in 
objective indicators of obesity.  It is now becoming quite clear that the management of obesity in patients 
with SMI requires early recognition, frequent monitoring, multidisciplinary treatment and approaches to 
build the motivation of patients to address potential/actual health risks (Manu et al., 2015; Mitchell and 
DeHert, 2015). The CHIP intervention contains these important elements, but in this instance it has not been 
used to facilitate early recognition of cardiometabolic health risks. If the CHIP intervention is started at the 
first point of contact with people with a SMI this may serve to off-set the build-up of cardiometabolic risk 
factors rather than intervening once a related physical illness has been identified (Mitchell and DeHert, 
2015). Our recently published HIP-T quasi experimental study involving 105 people with schizophrenia in 
Thailand (Meepring et al., 2016) showed a statistically significant reduction of average BMI (3.5% change, 
p<0.001), while a post-hoc subgroup analysis of patients (n=25) with early psychosis (i.e., not more than one-
year onset of the illness) found a potentially clinically significant improvement41 of >5% reduction of BMI 
(p=0.01, Cohen’s d=0.32). Suggesting that the CHIP intervention is likely to be more effective in patients with 
early stage of psychosis recently prescribed antipsychotics than in those patients with a longer duration of 
SMI. People with early stage psychosis may be more receptive towards interventions designed to raise 
awareness of the importance of preventing physical health problems and to enhance motivation/self-
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efficacy for managing health than those people who have a longer duration of illness (Carney, Bradshaw and 
Yung, 2016).  Service users who have experienced psychosis for long periods may subsequently develop 
cognitive impairments, marked negative symptoms and metabolic side effects from antipsychotics. All of 
these illness/treatment-related consequences can present significant barriers towards building an 
individual’s capability, opportunities, and motivation to make healthy lifestyle changes (Michie et al., 2015; 
Armitage and Conner, 2001).   
 
In terms of acceptability the intervention and feasibility of conducting a full-scale study; the CHIP participants 
were significantly more satisfied with their physical healthcare than TAU patients at one-year, suggesting 
that the CHIP intervention is viewed as being helpful by patients. Similarly, the CHIP CPNs viewed the 
approach as being generally useful and acceptable from their perspectives. The audit of randomly selected 
clinical notes suggests that CPNs fidelity to the intervention was maintained in at least half of cases. The 
attrition rate was also relatively low for this patient group (11%, 15 participants), suggesting that patients 
viewed participation in the trial as being acceptable. 
 
Study limitations 
The study limitations should be considered when interpreting the results. The lack of blinding of outcome 
measurement may have produced an expectation or response bias, the health behaviours were self-
reported by participants and not objectively verified, and the sample size for this pilot trial has resulted in 
an inadequate powered study to detect a small effect size for the primary outcome measure after 
adjusting for the clustering effect and baseline scores. However, the process of randomly selecting patient 
participants and randomisation of patients into treatment arms adds to the study’s internal validity.    
 
Conclusions: 
The results of this study indicate that it is feasible to conduct a full-scale RCT of the CHIP in future. Both 
patients and CPNs generally viewed the approach as being acceptable and useful. The CHIP is a low risk and 
easily accessible intervention that could result in modest improvements in the physical well-being of 
people with SMI. Future studies of the CHIP using the PCS of the SF12v2 as a primary outcome measure 
should consider using an effect size of 0.42 for sample size calculations.     
  
Relevance for clinical practice: 
The study findings provide further evidence that people with SMI will engage effectively in health-check 
interventions designed to improve their physical well-being when these are conducted by their CPNs. 
Physical health checks and associated brief motivational interviewing interventions should be conducted 
frequently and as early as possible in treatment to maximise the potential benefits.   
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Table 1:  Baseline socio-demographic and clinical characteristics of the CHIP and TAU groups 
 
Characteristics 
CHIP 
 (n= 69) 
TAU 
(n= 68) 
Test 
value  
df P 
Gender (f, %)   2.10a 1 0.17 
Male 
Female 
29, 42.0 
40, 58.0 
37, 54.4 
31, 45.6 
   
Age (years, mean±SD) 
47.8±9.2 46.8± 10.4 0.59b  135 0.56 
Education level (f, %) 
  1.12a 2 0.57 
Primary school or below 25, 36.2 19, 27.9    
Secondary school 37, 53.6 42, 61.8    
College or University 7, 10.1 7, 10.3    
Marital status (f, %)   0.67 a 4 0.96 
Single 
Married 
Divorced 
Widowed 
Other 
23, 33.3 
24, 34.8 
13, 18.8 
3, 4.3 
6, 8.7 
19, 27.9 
27, 39.7 
12, 17.6 
3, 4.4 
7, 10.3 
   
Living situation (f, %)   3.19 a 3 0.36 
    With family 
     Alone 
     Hostel 
     Other  
43, 62.3 
16, 23.2 
9, 13.0 
0, 0.0 
44, 64.7 
17, 25.0 
5, 7.4 
2, 2.9 
   
Financial support (f, %)   0.86 a 2 0.65 
   Government benefits 
    Family  
    None 
58, 84.1 
5, 7.2 
6, 8.7 
55, 80.1 
8, 11.8 
5, 7.4 
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Primary psychiatric diagnosis (f, %)   2.36 a 3 0.50 
Schizophrenia 
Major depression  
Bipolar affective disorder 
Other psychotic disorders 
39, 56.5 
16, 23.2 
9, 13.0 
5, 7.2 
37, 54.4 
17, 25.0 
5, 7.4 
9, 13.2 
   
Duration of psychiatric illness 
(months, mean±SD) 
 
170.4±136.6  
 
160.9±126.9 
 
0.42b 
 
133 
 
0.68 
Number of previous psychiatric 
admissions (mean±SD) 
3.44±4.6 2.54±2.81 1.35 b 129 0.18 
Physical illness diagnosis  (f, %)      
Diabetes 
Hypertension 
Dyslipidaemia 
10, 14.5 
9, 13.0 
5, 7.2 
7, 10.3 
4, 5.8 
0, 0.0 
0.61 a 
2.13a 
5.20 a 
1 
1 
1 
0.44 
0.15 
0.06* 
Physical state indicators (mean±SD)      
   BMI (kg/m2) 
   Waist circumference (cm) 
   Pulse (bpm) 
   Systolic BP (mm/hg) 
   Diastolic BP (mm/hg) 
   Total Cholesterol 
   LDL cholesterol 
   HDL cholesterol 
   Serum glucose 
24.05±3.8  
85.8±12.5 
78.0±9.6 
120.9±14.2 
76.8±9.3 
4.9±1.1 
2.8±0.8 
1.3±0.4 
5.5±1.5 
25.13±3.5 
85.2±10.1 
85.8±11.4 
125.9±12.5 
78.4±8.7 
4.9±0.9 
2.9±0.8 
1.2±0.4 
5.5±1.6 
1.72b 
0.29b 
4.33 b 
2.21 b 
1.06 b 
0.02 b 
0.62 b 
1.16b 
0.05b 
134 
134 
134 
135 
135 
111 
101 
104 
130 
0.09 
0.76 
0.001* 
0.03* 
0.29 
0.99 
0.53 
0.25 
0.96 
Type of antipsychotic medication (f,%)      
Conventional antipsychotics 
Atypical antipsychotics  
Long acting Antipsychotic injections 
20, 28.9 
44, 63.8 
18, 26.1  
22, 32.4 
44, 64.7 
17, 25.0 
1.44a 
0.01a 
0.02a  
1 
1 
1 
0.21 
0.91 
0.88 
Number of different antipsychotics 1.1, 0.6 1.1, 0.7 0.26 a 135 0.80 
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(mean±SD) 
Note: CHIP, Chinese Health Improvement Profile ; TAU, Treatment-As-Usual. 
a Tested by χ2  
b Tested by Independent Samples T-test. 
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Table 2: Data analysis of the primary outcome 
Variable CHIP 
 
 
mean±SE 
TAU 
 
 
mean±SE 
ICC Difference 
(adjusted for 
clustering) 
mean±SE 
P-value 
(Adjusted for 
clustering) 
PCS-12 (Baseline) 47.0±0.8 45.9±0.8 0.061 1.1±1.5 0.474  
PCS-12 (6months) 
PCS-12 (6months) 
Adjusted for baseline 
49.6±1.0 48.1±1.0 0.009 1.5±1.4 
1.1±1.3 
0.310  
0.400 
PCS-12 (12 months) 50.7±0.7 47.5±1.1 0.158 3.2±2.1 0.149  
PCS-12 (12 months) 
adjusted for baseline 
   2.7±1.7 0.138 
 
Table 3: Data analysis for the secondary outcomes 
Variable CHIP 
 
 
mean±SE 
TAU 
 
 
mean±SE 
ICC Difference 
(adjusted for 
clustering) 
mean±SE 
P-value 
(Adjusted for 
clustering) 
MCS-12 (Baseline) 43.8±1.5 45.2±1.3 0.058 -1.4±2.3 0.551  
MCS-12 (6months) 47.0±1.2 45.3±0.9 0.162 1.78±2.4 0.474  
MCS-12 (6months) 
adjusted for baseline 
scores 
   1.93±2.3 0.416 
MCS-12 (12 months) 48.8±1.1 46.0±0.9 0.059 2.8±1.8 0.147  
MCS-12 (12 months) 
adjusted for baseline 
scores 
   3.2±1.6 0.077 
BMI follow-up 24.3±0.5 25.1±0.5 0.130 -0.7±1.0 0.464  
      
Waist circumference 
follow-up 
85.5±1.6 84.9±1.2 0.218 0.6±3.4 0.856  
      
Pulse follow-up 77.6±1.2 85.4±1.1 0.124 -7.8±2.3 0.006* 
      
Systolic BP follow-up 118.7±2.1 123.6±1.5 0.224 -4.9±4.3 0.278  
      
Diastolic BP follow-up 75.6±1.4 77.1±1.0 0.147 -1.5±2.5 0.554  
      
Total Cholesterol 
Follow-up 
4.3±0.2 4.6±0.2 0.397 -0.3±0.5 0.569  
*significant difference (p≤0.05) 
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Table 4: CHIP flagged items at baseline and one-year follow-up  
 
CHIP items 
(Patient classification changes 
baseline to follow-up)  
 
Baseline (n=69) 
N (valid %)^ 
Follow-up (n=59) 
N (valid %)^ 
p value (Test result) 
BMI  
Red 
Green 
(Improved=6, Deteriorated=6) 
 
42 (60.9) 
27 (39.1) 
 
35 (60.3) 
23 (39.7) 
 
p= 1.000† 
Waist circumference 
Red 
Green 
(Improved=5, Deteriorated=5) 
 
38 (55.1) 
30 (44.1) 
 
31 (54.4) 
26 (45.6) 
 
p=1.000† 
Blood pressure 
Red 
Green 
(Improved=3, Deteriorated=2) 
 
6 (8.7) 
63 (91.3) 
 
3 (5.2) 
55 (94.8) 
 
p=1.000† 
Pulse 
Red 
Green 
(Improved=0, Deteriorated=0)  
 
1(1.4) 
68 (98.6) 
 
1 (1.7) 
57 (98.3) 
 
p=1.000† 
Liver Function Test 
Red 
Yellow 
Green 
(Improved=13, Deteriorated=14) 
 
42 (60.9) 
12 (17.4) 
15 (21.7) 
 
35 (60.3) 
10 (17.2) 
13 (22.4) 
 
p=.564 a 
Total Cholesterol 
Red 
Yellow 
Green 
(Improved=5, Deteriorated=6) 
 
6 (8.8) 
27 (39.7) 
35 (51.5) 
 
4 (6.9) 
24 (41.4) 
30 (51.7) 
 
p=.366 a 
LDL Cholesterol 
Red 
Yellow 
Green 
(Improved=3, Deteriorated=7) 
 
5 (7.2) 
16 (23.2) 
48 (69.6) 
 
8 (13.8) 
10 (17.2) 
40 (69.0) 
 
p=1.000 
HDL Cholesterol 
Red 
Yellow 
Green 
(Improved=8, Deteriorated=7) 
 
26 (38.2) 
15 (22.1) 
27 (39.7) 
 
20 (34.5) 
10 (17.2) 
28 (48.3) 
 
p=.617 a 
Triglycerides 
Red 
Yellow 
Green 
(Improved=8, Deteriorated=6) 
 
13 (21.0) 
19 (30.6) 
30 (48.4) 
 
14 (24.1) 
10 (17.2) 
34 (58.6) 
 
p=.593 a 
Serum glucose 
Red 
 
5 (7.5) 
 
5 (8.6) 
 
p=.059† 
  26  
Yellow 
Green 
(Improved=1, Deteriorated=6) 
3 (4.3) 
59 (88.1) 
4 (6.9) 
48 (82.8) 
Prostate/testicles (male, 
baseline n= 29) 
Red 
Yellow 
Green 
(Improved=5, Deteriorated=0) 
 
 
28 (93.3) 
0 (0.0) 
1 (3.3) 
 
 
17 (77.3) 
0 (0.0) 
5 (22.7) 
 
 
p=.025a 
Cervical smear (female, baseline 
n=40) 
Red 
Green 
(Improved= 5, Deteriorated=1) 
 
 
24 (60.0) 
16 (40.0) 
 
 
17 (47.2) 
19 (52.8) 
 
 
p=.375† 
Sleep 
Red 
Yellow 
Green 
(Improved= 7, Deteriorated=4) 
 
1 (1.4) 
29 (42.0) 
39 (56.5) 
 
1 (1.7) 
23 (39.7) 
34 (49.3) 
 
p=..564 a 
Oral hygiene 
Red 
Yellow 
Green 
(Improved= 11, Deteriorated=4) 
 
12 (17.4) 
13 (18.8) 
44 (63.8) 
 
11 (19.0) 
6 (10.3) 
41 (70.7) 
 
p=.346 
Eye checks 
Red 
Yellow 
Green 
(Improved=9, Deteriorated=11) 
 
11 (16.2) 
7 (10.3) 
50 (73.5) 
 
15 (25.9) 
2 (3.4) 
40 (69.0) 
 
p=.127 a 
Feet check 
Red 
Green 
(Improved=18, Deteriorated=1) 
 
30 (43.5) 
39 (56.5) 
 
8 (13.8) 
50 (86.2) 
 
 
p<.0001† 
Breast checks  
Red 
Green 
(Improved=14, Deteriorated=0) 
 
42 (61.8) 
26 (38.2) 
 
22 (37.9) 
35 (60.3) 
 
 
p=.002† 
Menstrual cycle (female, n=40) 
Red 
Green   
(Improved= 1, Deteriorated=9) 
 
3 (7.9) 
35 (92.1) 
 
12 (33.3) 
23 (63.9) 
 
 
p=.021† 
Smoking 
Red 
Green  
(Improved=1, Deteriorated=0)  
 
24 (34.8) 
45 (65.2) 
 
19 (32.8) 
39 (67.2) 
 
p=1.000† 
Physical activity 
Red 
Yellow 
 
43 (62.3) 
13 (18.8) 
 
27 (46.6) 
16 (27.6) 
 
p=.847 a 
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Green  
(Improved=20, Deteriorated=8)  
13 (18.8) 15 (25.9) 
Alcohol use 
Red 
Yellow 
Green  
(Improved=1, Deteriorated=1)  
 
2 (2.9) 
1 (1.4) 
66 (95.7) 
 
0 (0.0) 
3 (5.2) 
55 (94.8) 
 
p=.157 a 
Diet (fruit and vegetables) 
Red 
Yellow 
Green   
(Improved=13, Deteriorated=3) 
 
1 (1.4) 
21 (30.4) 
47 (68.1) 
 
1 (1.7) 
9 (15.5) 
48 (82.8) 
 
 
p=.008a 
Diet (meat) 
Red 
Yellow 
Green  
(Improved=11, Deteriorated=10)  
 
8 (11.8) 
16 (23.5) 
44 (64.7) 
 
3 (5.2) 
19 (32.8) 
36 (62.1) 
 
p=.827 a 
Diet (rice) 
Red 
Yellow 
Green   
(Improved=16, Deteriorated=8). 
 
5 (7.2) 
28 (40.6) 
36 (52.2) 
 
3 (5.2) 
18 (31.0) 
37 (63.8) 
 
 
p=.041a 
Caffeine intake 
Red 
Yellow 
Green  
(Improved=2, Deteriorated=2)  
 
0 (0) 
3 (4.3) 
66 (95.7) 
 
0 (0.0) 
3 (5.2) 
55 (94.8) 
 
p=1.000 a 
Fluid intake 
Red 
Yellow 
Green   
(Improved= 13, Deteriorated=1) 
 
3 (4.3) 
16 (23.2) 
50 (72.5) 
 
0 (0.0) 
6 (10.3) 
52 (89.7) 
 
 
p=.001a 
Drug use  
Red 
Green 
(Improved=0, Deteriorated=1)   
 
1 (1.4) 
68 (95.7) 
 
2 (3.4) 
56 (96.6) 
 
p=1.000† 
Safe sex 
Red 
Green  
(Improved=5, Deteriorated=0)  
 
6 (8.7) 
62 (89.9) 
 
0 (0.0) 
58 (100) 
 
p=.063† 
Sexual functioning 
Red 
Green  
(Improved=0, Deteriorated=1)  
 
1 (1.4) 
68 (98.6) 
 
2 (3.4) 
56 (96.6) 
 
p=1.000† 
Bowels 
Red 
Yellow 
Green  
 
11 (15.9) 
0 (0.0) 
58 (84.1) 
 
5 (8.6) 
2 (3.4) 
51 (87.9) 
 
p=1.000† 
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^Some missing/unreported data at baseline and follow-up – valid percentages used 
† McNemar test  
# Wilcoxon signed rank test 
a Friedman’s two-way ANOVA – ordinal variables coded as: 1 (Green) no concern, 2 (Yellow) possible concern, 3 (Red) 
high concern. 
 
 
 
 
 
 
 
 
 
 
 
(Improved=7, Deteriorated=4)  
Urine problems 
Red 
Green 
(Improved=3,Deteriorated=0)   
 
5 (7.2) 
64 (92.8) 
 
1 (1.7) 
57 (98.3) 
 
p=.250† 
Regular health monitoring 
Red 
Yellow 
Green  
(Improved=8, Deteriorated=10)  
 
11 (15.9) 
4 (5.8) 
54 (78.3) 
 
5 (8.6) 
10 (17.2) 
43 (74.1) 
 
p=.346a 
Total Red flags (Mean, SD)  
Total Yellow flags (Mean, SD)  
Total Green flags (Mean, SD) 
6.61 (2.99) 
3.56 (2.39) 
20.16 (3.75) 
5.66 (2.48) 
3.15 (2.04) 
21.64 (3.50) 
p=.005#, (Z=-2.81) 
p=.353#, (Z= -0.93) 
p=.002#, (Z=-3.13) 
